Sector News

AstraZeneca Non-Executive Director Bruce Burlington to retire

August 17, 2017
Life sciences

AstraZeneca PLC on Wednesday said Non-Executive Director Bruce Burlington will retire from the board on August 31.

The FTSE 100-listed pharmaceutical said Burlington, who joined the board in 2010, will also step down as a member of the audit committee, the nomination and governance committee and from his role as chairman of the science committee.

Chairman Leif Johansson said: “Bruce has been an exemplary director who has made a significant contribution to the board’s work over many years. We have valued his insightful and frank participation as a board member, and chairman of the science committee during a period of innovation-led transformation at AstraZeneca.

“His diligence and commitment to the work of the audit committee and the nomination and governance committee should also be acknowledged.”

By Maryam Cockar

Source: Alliance News

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.